Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer
Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn the effects (both good and bad) that celecoxib has on
prostate cancer and patients with prostate cancer. This study is looking at what effects
celecoxib has on prostate specific antigen (PSA) level. PSA is a marker specific to prostate
cancer. An increase or decrease in this level in the blood can indicate if a patient's
prostate cancer is getting worse or better.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Emerson Hospital, Concord, MA Hartford Hospital Lowell General Hospital M.D. Anderson Cancer Center Massachusetts General Hospital Pfizer University of Michigan Cancer Center University of Michigan Rogel Cancer Center